Heterocyclic oxime compounds

US8507676B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Miao Dai · Shanghai, CN
• Xingnian Fu · Shanghai, CN
• Feng He · Nanhu, CN
• Lei Jiang · Shanghai, CN
• Yue Li · Shanghai, CN
• Fang Liang · Carlsbad, US
• Lei Liu · Thousand Oaks, US
• Yuan Mi · San Diego, US
• Yao-Chang Xu · Indianapolis, US
• Guoliang Xun · 林湖乡, CN
• Xiaoxia YAN · Shanghai, CN
• Zhengtian Yu · Shanghai, CN
• Ji Zhang · Dongguan, CN

Key dates

• Filing date: Aug 6, 2012
• Grant date: Aug 13, 2013
• Expiry date: Aug 6, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula (I) and salts thereof:wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).